1. 2019
  2. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism

    Boeckmans, J., Natale, A., Rombaut, M., Buyl, K., Rogiers, V., De Kock, J., Vanhaecke, T. & Rodrigues, R., 21 Dec 2019, In : Cells. 9, 1, p. 1-20 20 p., 37.

    Research output: Contribution to journalArticleResearchpeer-review

  3. Transcriptomics data of a human in vitro model of non-alcoholic steatohepatitis exposed to elafibranor

    Boeckmans, J., Buyl, K., Natale, A., Vandenbempt, V., Branson, S., De Boe, V., Rogiers, V., De Kock, J., Marcelino Rodrigues, R. & Vanhaecke, T., 1 Aug 2019, In : Data in Brief. 25, p. 104093 6 p., 104093.

    Research output: Contribution to journalArticleResearchpeer-review

  4. 2018
  5. Comment to ‘Letter to the editor: Human-based systems: Mechanistic NASH modelling just around the corner?’

    Boeckmans, J., Natale, A., Buyl, K., De Kock, J., Rogiers, V., Vanhaecke, T. & Marcelino Rodrigues, R., Nov 2018, In : Pharmacological Research. 137, 31475, p. 282-283 2 p.

    Research output: Contribution to journalComment/debateResearch

  6. Human-based systems: Mechanistic NASH modelling just around the corner?

    Boeckmans, J., Natale, A., Buyl, K., Rogiers, V., De Kock, J., Vanhaecke, T. & Marcelino Rodrigues, R., 1 Aug 2018, In : Pharmacological Research. 134, p. 257-267 11 p.

    Research output: Contribution to journalArticleResearchpeer-review

  7. Elafibranor restores lipogenic gene expression in a human skin stem cell-derived non-alcoholic fatty liver disease (NAFLD) model

    Boeckmans, J., Natale, A., Buyl, K., De Kock, J., Rogiers, V., Vanhaecke, T. & Marcelino Rodrigues, R., 2018, Elafibranor restores lipogenic gene expression in a human skin stem cell-derived non-alcoholic fatty liver disease (NAFLD) model. p. 354-355 2 p.

    Research output: Chapter in Book/Report/Conference proceedingMeeting abstract (Book)Research

Previous 1 2 3 4 Next

ID: 73187